Identifying CNS biomarkers: BOs will undergo molecular and morphological analyses to identify validated or potential AD biomarkers, previously detected in corresponding in vivo anatomical structures, including toxic protein aggregates such as β-amyloid and tau proteins, which are crucial for comparing AD hallmarks in vivo. This evidence concerns the gene MAPT and Alzheimer disease.